Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
| ▸ | PPARG | P37231 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.83 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355331 | 0.91 | MEN1 (1.00) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL16593265 | 0.91 | MEN1 (1.00) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL19269179 | 0.91 | MEN1 (0.69) | MEN1USP2POLBPPARGBLM | |
| Water SCHEMBL7715721 | 0.90 | MEN1 (0.98) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29662906 | 0.90 | MEN1 (0.82) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL19962197 | 0.90 | MEN1 (0.82) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL31011003 | 0.89 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29352150 | 0.89 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL31011004 | 0.89 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL18483 | 0.89 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030864-B2 | Small molecule anticancer agents, combinations and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030864-B2 | Small molecule anticancer agents, combinations and uses thereof | MKI67, TP53, PCNA | MEN1 1485/4885USP2 3220/4885POLB 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.